Inhibition of autophagy enhances apoptosis induced by proteasome inhibitor bortezomib in human glioblastoma U87 and U251 cells

Molecular and Cellular Biochemistry

Volumn 385, Issue 1-2, 2014, Pages 265-275

  Zhang, Xudong ^a   Li, Weiming ^a   Wang, Chunlan ^b   Leng, Xiangyang ^a   Lian, Shulin ^a   Feng, Jingbin ^c   Li, Jinliang ^d   Wang, Hailiang ^e  

^a CHANGCHUN UNIVERSITY   (China)

^b Department of Otolaryngology and Head and Neck Surgery   (China)

^c People's Hospital of Sanya   (China)

^d Yong Plastic Surgery Clinic   (China)

^e JILIN UNIVERSITY   (China)

Author keywords

Apoptosis; Autophagy; Bortezomib; Glioblastoma

Indexed keywords

3 METHYLADENINE; BORTEZOMIB; CASPASE 3; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PROTEASOME; PROTEIN; PROTEIN ATG7; PROTEIN BAX; PROTEIN BCL 2; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL CULTURE; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; GLIOBLASTOMA; GROWTH INHIBITION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ADENINE; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; BORONIC ACIDS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; GLIOBLASTOMA; HUMANS; MITOCHONDRIA; PROTEASOME INHIBITORS; PYRAZINES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; UBIQUITIN-ACTIVATING ENZYMES;

EID: 84890448328     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-013-1835-z     Document Type: Article

References (37)

1. Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY (2003) Primary brain tumours in adults. Lancet 361:323-331
2. Shapiro JR (2002) Genetic alterations associated with adult diffuse astrocytic tumors. Am J Med Genet 115:194-201
3. Anton K, Baehring JM, Mayer T (2012) Glioblastoma multiforme: overview of current treatment and future perspectives. Hematol Oncol Clin North Am 26:825-853
4. Black KL, Pikul BK (1999) Gliomas: past, present, and future. Clin Neurosurg 45:160-163
5. Bleeker FE, Molenaar RJ, Leenstra S (2012) Recent advances in the molecular understanding of glioblastoma. J Neurooncol 108:11-27
6. Marumoto T, Saya H (2012) Molecular biology of glioma. Adv Exp Med Biol 746:2-11
7. Sayers TJ, Murphy WJ (2006) Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy. Cancer Immunol Immunother 55:76-84
8. Mujtaba T, Dou QP (2011) Advances in the understanding of mechanisms and therapeutic use of bortezomib. Discov Med 12:471-480
9. Frankland-Searby S, Bhaumik SR (2012) The 26S proteasome complex: an attractive target for cancer therapy. Biochim Biophys Acta 1825:64-76
10. Ludwig H, Khayat D, Giaccone G, Facon T (2005) Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer 104:1794-1807
11. Caravita T, de Fabritiis P, Palumbo A, Amadori S, Boccadoro M (2006) Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies. Nat Clin Pract Oncol 3:374-387
12. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR (2006) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24:431-436
13. Hamilton AL, Eder JP, Pavlick AC, Clark JW, Liebes L, Garcia-Carbonero R, Chachoua A et al (2005) Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. J Clin Oncol 23:6107-6116
14. Blaney SM, Bernstein M, Neville K, Ginsberg J, Kitchen B, Horton T, Berg SL et al (2004) Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). J Clin Oncol 22:4804-4809
15. Messersmith WA, Baker SD, Lassiter L, Sullivan RA, Dinh K, Almuete VI, Wright JJ et al (2006) Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res 12:1270-1275
16. Fennell DA, McDowell C, Busacca S, Webb G, Moulton B, Cakana A, O'Byrne KJ et al (2012) Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma. J Thorac Oncol 7:1466-1470
17. Piperdi B, Walsh WV, Bradley K, Zhou Z, Bathini V, Hanrahan-Boshes M, Hutchinson L et al (2012) Phase-I/II study of bortezomib in combination with carboplatin and bevacizumab as first-line therapy in patients with advanced non-small-cell lung cancer. J Thorac Oncol 7:1032-1040
18. Besse B, Planchard D, Veillard AS, Taillade L, Khayat D, Ducourtieux M, Pignon JP et al (2012) Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer. Lung Cancer 76:78-83
19. Marino G, Lopez-Otin C (2004) Autophagy: molecular mechanisms, physiological functions and relevance in human pathology. Cell Mol Life Sci 61:1439-1454
20. Patel AS, Lin L, Geyer A, Haspel JA, An CH, Cao J, Rosas IO et al (2012) Autophagy in idiopathic pulmonary fibrosis. PLoS One 7:e41394
21. Chen S, Rehman SK, Zhang W, Wen A, Yao L, Zhang J (2010) Autophagy is a therapeutic target in anticancer drug resistance. Biochim Biophys Acta 1806:220-229
22. Ding ZB, Hui B, Shi YH, Zhou J, Peng YF, Gu CY, Yang H et al (2011) Autophagy activation in hepatocellular carcinoma contributes to the tolerance of oxaliplatin via reactive oxygen species modulation. Clin Cancer Res 17:6229-6238
23. Shi YH, Ding ZB, Zhou J, Hui B, Shi GM, Ke AW, Wang XY et al (2011) Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis. Autophagy 7:1159-1172
24. Dalby KN, Tekedereli I, Lopez-Berestein G, Ozpolat B (2010) Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. Autophagy 6:322-329
25. Pédeboscq S, L'Azou B, Passagne I, De Giorgi F, Ichas F, Pometan JP, Cambar J (2008) Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells. J Exp Ther Oncol 7:99-111
26. Jane EP, Premkumar DR, Pollack IF (2011) Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway. Mol Cancer Ther 10:198-208
27. Pellom ST Jr, Shanker A (2012) Development of Proteasome Inhibitors as Therapeutic Drugs. J Clin Cell Immunol S 5:5
28. Thompson JL (2013) Carfilzomib a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma. Ann Pharmacother 47:56-62
29. Jones DR, Moskaluk CA, Gillenwater HH, Petroni GR, Burks SG, Philips J, Rehm PK et al (2012) Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer. J Thorac Oncol 7:1683-1690
30. Guo N, Peng Z (2013) MG132, a proteasome inhibitor, induces apoptosis in tumor cells. Asia Pac J Clin Oncol 9:6-11
31. Schmidt N, Alloway RR, Walsh RC, Sadaka B, Shields AR, Girnita AL, Hanseman DJ et al (2012) Prospective evaluation of the toxicity profile of proteasome inhibitor-based therapy in renal transplant candidates and recipients. Transplantation 94:352-361
32. Chauhan D, Hideshima T, Anderson KC (2005) Proteasome inhibition in multiple myeloma: therapeutic implication. Annu Rev Pharmacol Toxicol 45:465-476
33. Aghajanian C, Soignet S, Dizon DS, Pien CS, Adams J, Elliott PJ, Sabbatini P et al (2002) A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 8:2505-2511
34. Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, Chen G, Mukherjee C et al (2006) Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell 10:51-64
35. Amaravadi RK, Yu D, Lum JJ, Bui T, Christophorou MA, Evan GI, Thomas-Tikhonenko A et al (2007) Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest 117:326-336
36. Carew JS, Nawrocki ST, Kahue CN, Zhang H, Yang C, Chung L, Houghton JA et al (2007) Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood 110:313-322
37. Levine B, Yuan J (2005) Autophagy in cell death: an innocent convict? J Clin Invest 115:2679-2688